Adult Medulloblastoma Clinical Trial
Official title:
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.
PRIMARY OBJECTIVES:
I. To estimate the efficacy of GDC-0449 (vismodegib) treatment for adult patients with
recurrent or refractory medulloblastoma, as measured by the objective response rates for
patients without (Stratum A) and with (Stratum B) evidence of activation of Sonic Hedgehog
(SHH) signaling pathway tumors.
SECONDARY OBJECTIVES:
I. To assess the safety and tolerability of GDC-0449 administered on a once daily schedule.
II. To estimate the duration of objective response and progression-free survival (PFS).
III. To characterize the pharmacokinetics (plasma and cerebrospinal fluid) of GDC-0449 in
adults with refractory medulloblastoma.
IV. To document pathologic and genomic methods to identify CNS tumors with activation of the
PTCH/SHH pathway.
V. To describe the objective responses observed in patients whose pathologic assessment of
tumor result in unknown (Stratum C) evidence of activation of Sonic Hedgehog (SHH) signaling
pathway tumors.
OUTLINE: This is a multicenter study. Patients are stratified according to PTCH/Sonic
Hedgehog signaling pathway activation (inactivated vs activated vs unknown).
Patients receive vismodegib orally (PO) once daily on days 1-28. Treatment repeats every 28
days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically for up to 12
months.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT01977677 -
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00019578 -
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
|
Phase 1 | |
Completed |
NCT01119599 -
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Terminated |
NCT00110032 -
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
|
Phase 1 | |
Terminated |
NCT01234805 -
Yoga Therapy in Treating Patients With Malignant Brain Tumors
|
N/A | |
Terminated |
NCT02967380 -
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
|
N/A | |
Completed |
NCT01869725 -
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
|
Phase 2 |